File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cardiomyocytes derived from pluripotent stem cells: Progress and prospects from China

TitleCardiomyocytes derived from pluripotent stem cells: Progress and prospects from China
Authors
Issue Date2013
Citation
Experimental Cell Research, 2013, v. 319 n. 2, p. 120-125 How to Cite?
AbstractTransplantation of embryonic stem cell- or induced pluripotent stem cell-derived cardiomyocytes (CMs) represents one promising approach for the treatment of myocardial infarction and failing hearts. Cardiac differentiation systems from these pluripotent stem cells (PSCs) can also be employed to better understand early developmental biology, drug discovery, toxicology testing, and disease modeling. A prerequisite to attain these goals is the ability to generate functional CMs in an efficient and reliable way. The lack of CM maturation must also be overcome, and appropriate methods for introducing PSC-CMs into heart while maintaining cell viability must be optimized. The past few years have seen major advances both in the differentiation, characterization and application of these cells to biological systems. Here we review recent progress, especially those performed in China, in basic stem cell biology involving studies of cardiogenesis and CMs through PSC differentiation, approaches for chamber-specific CM differentiation, maturation processes involving regulation of intracellular Ca2+ signals, and applications. © 2012 Elsevier Inc.
Persistent Identifierhttp://hdl.handle.net/10722/195207
ISSN
2015 Impact Factor: 3.378
2015 SCImago Journal Rankings: 1.900
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYang, H-T-
dc.contributor.authorZhang, M-
dc.contributor.authorHuang, J-
dc.contributor.authorLiang, H-
dc.contributor.authorZhang, P-
dc.contributor.authorBoheler, KR-
dc.date.accessioned2014-02-25T01:40:18Z-
dc.date.available2014-02-25T01:40:18Z-
dc.date.issued2013-
dc.identifier.citationExperimental Cell Research, 2013, v. 319 n. 2, p. 120-125-
dc.identifier.issn0014-4827-
dc.identifier.urihttp://hdl.handle.net/10722/195207-
dc.description.abstractTransplantation of embryonic stem cell- or induced pluripotent stem cell-derived cardiomyocytes (CMs) represents one promising approach for the treatment of myocardial infarction and failing hearts. Cardiac differentiation systems from these pluripotent stem cells (PSCs) can also be employed to better understand early developmental biology, drug discovery, toxicology testing, and disease modeling. A prerequisite to attain these goals is the ability to generate functional CMs in an efficient and reliable way. The lack of CM maturation must also be overcome, and appropriate methods for introducing PSC-CMs into heart while maintaining cell viability must be optimized. The past few years have seen major advances both in the differentiation, characterization and application of these cells to biological systems. Here we review recent progress, especially those performed in China, in basic stem cell biology involving studies of cardiogenesis and CMs through PSC differentiation, approaches for chamber-specific CM differentiation, maturation processes involving regulation of intracellular Ca2+ signals, and applications. © 2012 Elsevier Inc.-
dc.languageeng-
dc.relation.ispartofExperimental Cell Research-
dc.titleCardiomyocytes derived from pluripotent stem cells: Progress and prospects from China-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.yexcr.2012.09.011-
dc.identifier.pmid23022397-
dc.identifier.scopuseid_2-s2.0-84870733376-
dc.identifier.volume319-
dc.identifier.issue2-
dc.identifier.spage120-
dc.identifier.epage125-
dc.identifier.isiWOS:000312465900002-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats